Intratonsillar Immunotherapy: A Convenient and Effective Alternative to Subcutaneous Immunotherapy for Allergic Rhinitis
Research · 2025-01 · 8
DOI: 10.34133/research.0573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research, online erschienen am 16.01.2025. Verfasst von Tian Gu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rhinology and Allergy, Otolaryngology-Head and Neck Surgery Center, Renmin Hospital of Wuhan University, Wuhan 430060, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Allergen-specific immunotherapy (AIT) is the only treatment that addresses the root cause of immunoglobulin E (IgE)-mediated allergies, but conventional methods face challenges with treatment duration, patient compliance, and adverse effects. In this study, we propose intratonsillar immunotherapy (ITIT) as a new effective and safer route for AIT. Prior to clinical trials, we analyzed tonsil samples from human subjects to assess immune responses, measuring interleukin-4 (IL-4), IL-21, total IgE (tIgE), and allergen-specific IgE concentrations using ELISA and BioIC. Our results indicated that tonsils contained higher levels of allergen-specific IgE compared to peripheral blood. In the clinical phase, 120 allergic rhinitis (AR) patients were treated with either 3 intratonsillar allergen injections over 2 months or conventional subcutaneous immunotherapy (SCIT) over 1 year. ITIT demonstrated superior and faster symptom relief, especially in younger patients, while requiring markedly fewer doses and injections than SCIT. Immunological analysis revealed reduced eosinophil counts, increased regulatory T (T reg ) and follicular regulatory T (T FR ) cell levels, and a favorable shift in cytokine profiles. Adverse events were minimal, and the treatment showed high patient compliance. These findings suggest that ITIT could provide an effective, safer, and more convenient alternative to AIT.
Autor:innen und Institutionen
- Department of Rhinology and Allergy, Otolaryngology-Head and Neck Surgery Center, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
- Hubei Province Key Laboratory of Allergy and Immunity, Wuhan, China.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Gu, T., Zhang, W., Tan, L., Xiang, R., Liu, P., Huang, J., Deng, Q., Deng, Y., Tao, Z., Chen, S., & Xu, Y. (2025). Intratonsillar Immunotherapy: A Convenient and Effective Alternative to Subcutaneous Immunotherapy for Allergic Rhinitis. Research, 8. https://doi.org/10.34133/research.0573
Vancouver
Gu T, Zhang W, Tan L, Xiang R, Liu P, Huang J, et al. Intratonsillar Immunotherapy: A Convenient and Effective Alternative to Subcutaneous Immunotherapy for Allergic Rhinitis. Research. 2025;8. doi:10.34133/research.0573
BibTeX
@article{Gu2025,
author = {Gu, Tian and Zhang, Wei and Tan, Lu and Xiang, Rong and Liu, Peiqiang and Huang, Jingyu and Deng, Qin and Deng, Yuqin and Tao, Zezhang and Chen, Shiming and Xu, Yu},
title = {Intratonsillar Immunotherapy: A Convenient and Effective Alternative to Subcutaneous Immunotherapy for Allergic Rhinitis},
journal = {Research},
year = {2025},
volume = {8},
doi = {10.34133/research.0573}
}
EUVIMED